Related Experiment Video
Updated: Jul 11, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study
R O Millán-Guerrero1, R Isais-Millán, S Barreto-Vizcaíno
1Department of Neurology, Unidad de Investigación Médica en Epidemiología Clínica, Hospital General de Zona UMF No 1 IMSS, Colima, México.
European Journal of Neurology
|September 21, 2007
Summary
Subcutaneous histamine significantly reduced migraine intensity and duration, offering a novel therapeutic option for prophylaxis. This approach proved more effective than oral sodium valproate in a clinical trial.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine pathophysiology involves neurogenic edema.
- Histamine exhibits selective affinity for H3-receptors.
- Histamine may inhibit neurogenic edema, suggesting a therapeutic role.
Purpose of the Study:
- To evaluate subcutaneous histamine for migraine prophylaxis.
- To compare its efficacy against oral sodium valproate.
- To assess histamine's therapeutic potential in a clinical trial.
Main Methods:
- Ninety-two migraine patients were enrolled in a 12-week double-blind controlled trial.
- Subcutaneous histamine (1-10 ng twice weekly) vs. oral sodium valproate (500 mg daily).
- Assessed headache intensity, frequency, duration, analgesic intake, and MIDAS score.
Main Results:
- Histamine significantly reduced migraine intensity and duration (P < 0.001).
- Subcutaneous histamine led to a greater reduction in analgesic intake.
- No significant differences were observed in attack frequency or MIDAS scores.
Conclusions:
- Subcutaneous histamine demonstrated superior efficacy in migraine prophylaxis compared to oral sodium valproate.
- Histamine may offer a novel and effective treatment for resistant migraine cases.
- Further research into subcutaneous histamine for migraine is warranted.
